Compugen Boosts Cancer Treatment Potential with New Patent for COM902 and Antibody Combinations
Compugen Ltd., a leading clinical-stage cancer immunotherapy firm based in Israel, announced a significant expansion to its intellectual property portfolio with a newly granted U.S. patent. The patent, designated as U.S. Patent No. 12152084, covers the methodology of utilizing COM902—a highly promising reduced Fc anti-TIGIT antibody—in conjunction with both anti-PD-1 and anti-PVRIG antibodies for treating various forms of cancer. This patent represents a strategic extension of the protections around COM902, which has been identified as a potential game-changer in innovative cancer therapies.
The new U.S. patent not only reinforces Compugen's existing patents but also facilitates a more comprehensive application of COM902 alongside any available anti-PD-1 antibodies and anti-PVRIG antibodies. This advancement is crucial given the evolving landscape of cancer treatment options, which often require combination therapies to optimize patient outcomes. Anat Cohen-Dayag, Ph.D., the President and CEO of Compugen, emphasized the importance of this patent in the company’s strategy to deliver cutting-edge treatments while also enhancing shareholder value. "Recent data suggests potential advantages for anti-TIGIT therapies that lack an active Fc binder, like COM902. Our findings indicate that in certain tumor types, simply blocking TIGIT might not be adequate to achieve significant anti-tumor efficacy. Instead, concurrent inhibition of both PD-1 and PVRIG may be essential for maximizing patient benefit."
Compugen is at the forefront of cancer immunotherapy, utilizing its proprietary predictive computational discovery platform, Unigen™, to unearth novel therapeutic targets. The company conducts active research to further the therapeutic capabilities of its reigning candidates, including the first-in-class anti-PVRIG antibody, COM701, which is entering an adaptive platform trial aimed at assessing its monotherapy potential as well as its roles in future combinations with COM902 and other therapies. The patented technology surrounding COM902 is not anticipated to expire before August 2037 in the U.S., positioning Compugen well for future therapeutic developments.
Aside from COM902 and COM701, Compugen is also working through other promising immuno-oncology programs. Among these, COM503—a high-affinity anti-IL-18 binding protein antibody—is notably advanced. This program has received Investigational New Drug (IND) clearance from the FDA and has been licensed to Gilead. Compugen is headquartered in Holon, Israel, with a significant operational presence in San Francisco, California. The company is publicly traded on the Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN, making its innovations accessible to a broader investor audience.
The announcement of this new patent underscores Compugen's commitment to pioneering therapies that can tackle the complexities of cancer treatment, which typically requires multifaceted approaches due to the heterogeneous nature of tumors and their responses to therapy. As the company continues its path of innovation, the landscape of cancer immunotherapy stands on the brink of transformation, driven by the exciting developments that organizations like Compugen are spearheading.
Compugen's forward-looking statements highlight various challenges and opportunities as it manages its product pipeline and commercial strategies, including potential delays in clinical trials and partnerships. Nevertheless, with this latest patent, Compugen fortifies its position and widens the spectrum of its therapeutic capabilities, creating new paths for patient treatments that could significantly change the lives of those battling cancer.
The new U.S. patent not only reinforces Compugen's existing patents but also facilitates a more comprehensive application of COM902 alongside any available anti-PD-1 antibodies and anti-PVRIG antibodies. This advancement is crucial given the evolving landscape of cancer treatment options, which often require combination therapies to optimize patient outcomes. Anat Cohen-Dayag, Ph.D., the President and CEO of Compugen, emphasized the importance of this patent in the company’s strategy to deliver cutting-edge treatments while also enhancing shareholder value. "Recent data suggests potential advantages for anti-TIGIT therapies that lack an active Fc binder, like COM902. Our findings indicate that in certain tumor types, simply blocking TIGIT might not be adequate to achieve significant anti-tumor efficacy. Instead, concurrent inhibition of both PD-1 and PVRIG may be essential for maximizing patient benefit."
Compugen is at the forefront of cancer immunotherapy, utilizing its proprietary predictive computational discovery platform, Unigen™, to unearth novel therapeutic targets. The company conducts active research to further the therapeutic capabilities of its reigning candidates, including the first-in-class anti-PVRIG antibody, COM701, which is entering an adaptive platform trial aimed at assessing its monotherapy potential as well as its roles in future combinations with COM902 and other therapies. The patented technology surrounding COM902 is not anticipated to expire before August 2037 in the U.S., positioning Compugen well for future therapeutic developments.
Aside from COM902 and COM701, Compugen is also working through other promising immuno-oncology programs. Among these, COM503—a high-affinity anti-IL-18 binding protein antibody—is notably advanced. This program has received Investigational New Drug (IND) clearance from the FDA and has been licensed to Gilead. Compugen is headquartered in Holon, Israel, with a significant operational presence in San Francisco, California. The company is publicly traded on the Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN, making its innovations accessible to a broader investor audience.
The announcement of this new patent underscores Compugen's commitment to pioneering therapies that can tackle the complexities of cancer treatment, which typically requires multifaceted approaches due to the heterogeneous nature of tumors and their responses to therapy. As the company continues its path of innovation, the landscape of cancer immunotherapy stands on the brink of transformation, driven by the exciting developments that organizations like Compugen are spearheading.
Compugen's forward-looking statements highlight various challenges and opportunities as it manages its product pipeline and commercial strategies, including potential delays in clinical trials and partnerships. Nevertheless, with this latest patent, Compugen fortifies its position and widens the spectrum of its therapeutic capabilities, creating new paths for patient treatments that could significantly change the lives of those battling cancer.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.